Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Publication
, Journal Article
Muir, AJ; McHutchison, JG
Published in: Hepatology
December 2006
Duke Scholars
Published In
Hepatology
DOI
ISSN
0270-9139
Publication Date
December 2006
Volume
44
Issue
6
Start / End Page
1400 / 1403
Location
United States
Related Subject Headings
- Treatment Outcome
- Ribavirin
- Randomized Controlled Trials as Topic
- Intercellular Signaling Peptides and Proteins
- Humans
- Hepatitis C, Chronic
- Gastroenterology & Hepatology
- Erythropoietin
- Cost-Benefit Analysis
- Antiviral Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., & McHutchison, J. G. (2006). Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology, 44(6), 1400–1403. https://doi.org/10.1002/hep.21426
Muir, Andrew J., and John G. McHutchison. “Growth factors during HCV therapy may be "cost-effective", but are they "effective"?” Hepatology 44, no. 6 (December 2006): 1400–1403. https://doi.org/10.1002/hep.21426.
Muir AJ, McHutchison JG. Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology. 2006 Dec;44(6):1400–3.
Muir, Andrew J., and John G. McHutchison. “Growth factors during HCV therapy may be "cost-effective", but are they "effective"?” Hepatology, vol. 44, no. 6, Dec. 2006, pp. 1400–03. Pubmed, doi:10.1002/hep.21426.
Muir AJ, McHutchison JG. Growth factors during HCV therapy may be "cost-effective", but are they "effective"? Hepatology. 2006 Dec;44(6):1400–1403.
Published In
Hepatology
DOI
ISSN
0270-9139
Publication Date
December 2006
Volume
44
Issue
6
Start / End Page
1400 / 1403
Location
United States
Related Subject Headings
- Treatment Outcome
- Ribavirin
- Randomized Controlled Trials as Topic
- Intercellular Signaling Peptides and Proteins
- Humans
- Hepatitis C, Chronic
- Gastroenterology & Hepatology
- Erythropoietin
- Cost-Benefit Analysis
- Antiviral Agents